SANTA CLARA, Calif., Nov. 07, 2016 -- Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market for reduction of odor when patients are treated with the miraDry system. miraDry is now the first and only FDA cleared device for the non-invasive treatment of odor.
Mike Kleine, Chief Executive Officer of Miramar, said, “FDA clearance for odor reduction is a significant milestone in our product development strategy that further enhances the value proposition of the miraDry system for aesthetic practices. We believe it will allow our customers to expand the appeal of the miraDry procedure with the same easy-to-use, safe and effective system that treats underarm sweat and hair. We look forward to introducing this new labeling into the market and continuing to advance our other new product programs, including expanding the miraDry technology for use in hand sweat.”
“miraDry is proven to reduce underarm sweat by delivering localized heat to the area where the eccrine sweat glands reside, and in many patients we have observed that the device also thermally impacts and eliminates the apocrine glands that are responsible for bad body odor,” said E. Victor Ross, MD, director of the Laser and Cosmetic Dermatology Center at Scripps Clinic in San Diego, Calif. “It is important to our patients that we not only treat their sweat, but that we also significantly decrease the odor-causing secretions that are often more noticeable and disturbing.”
Miramar Lab's proprietary miraWave® technology – use of precisely controlled microwave energy – is the foundation of the miraDry system. This latest FDA clearance builds on the miraDry System’s existing indications for the treatment of underarm sweat and for the permanent reduction of unwanted underarm hair of all colors.
About Miramar Labs:
Miramar Labs, Inc.® is a global medical device company dedicated to bringing innovative and clinically proven applications to treat unmet needs in the aesthetic marketplace. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company’s first priority is the treatment of bothersome underarm sweat, an issue that hundreds of millions of people deal with daily. The miraDry® procedure has an established safety and efficacy profile with over 80,000 patients treated worldwide. Physicians and patients are encouraged to visit www.miramarlabs.com or www.miradry.com for additional information.
Contact: Investors: Brigid Makes Sr. Vice President & CFO Phone: 408.579.8700 Email: [email protected] Nick Laudico or Zack Kubow The Ruth Group 646-536-7030 / 7020 [email protected] [email protected] Bob Prag The Del Mar Consulting Group, Inc. (858) 794-9500 [email protected]


California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
FDA Approves Mitapivat for Anemia in Thalassemia Patients 



